Skip to content
Biodatica
Start free

Gilead Sciences

Bakersfield, California

OncologyantibodyFiled/ApprovedListed · GILD

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

2d agoTrial registeredJul 17, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Jul 1, 2026

    HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric Adenocarcinoma · RECRUITING · sponsor: Gilead Sciences · Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

    ClinicalTrials.gov · NCT07546812 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    May 19, 2026

    Advanced Microsatellite Stable Colorectal Cancer · RECRUITING · sponsor: Gilead Sciences · Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

    ClinicalTrials.gov · NCT07527858 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    May 29, 2025

    HIV-1-infection · COMPLETED · sponsor: Gilead Sciences · Study of GS-3242 in Participants With HIV-1; Substudy-05

    ClinicalTrials.gov · NCT07001319 (opens the source filing in a new tab)

  4. Trial

    PHASE3 registered

    Apr 4, 2025

    Extensive Stage Small Cell Lung Cancer (ES-SCLC) · RECRUITING · sponsor: Gilead Sciences · Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

    ClinicalTrials.gov · NCT06801834 (opens the source filing in a new tab)

  5. Trial

    Study registered

    Feb 21, 2025

    Breast Cancer · COMPLETED · sponsor: Gilead Sciences · A Qualitative Study on Advanced Breast Cancer Patients and Their Caregivers in Spain

    ClinicalTrials.gov · NCT06683482 (opens the source filing in a new tab)

  6. Trial

    PHASE1 registered

    Jan 9, 2024

    Advanced Solid Tumors · RECRUITING · sponsor: Gilead Sciences · Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

    ClinicalTrials.gov · NCT06167317 (opens the source filing in a new tab)

  7. Trial

    PHASE1 registered

    May 11, 2023

    Solid Tumor · ACTIVE_NOT_RECRUITING · sponsor: Gilead Sciences · Study of GS-4528 in Adults With Solid Tumors

    ClinicalTrials.gov · NCT05840224 (opens the source filing in a new tab)

  8. Trial

    PHASE2 registered

    Mar 16, 2023

    Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer · ACTIVE_NOT_RECRUITING · sponsor: Gilead Sciences · Study of Novel Treatment Combinations in Patients With Lung Cancer

    ClinicalTrials.gov · NCT05633667 (opens the source filing in a new tab)

  9. Trial

    PHASE3 registered

    Jul 25, 2022

    Triple Negative Breast Cancer, PD-L1 Positive · ACTIVE_NOT_RECRUITING · sponsor: Gilead Sciences · Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

    ClinicalTrials.gov · NCT05382286 (opens the source filing in a new tab)

  10. Trial

    PHASE1/PHASE2 registered

    Oct 20, 2021

    Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer, HR+/HER2- Metastatic Breast Cancer, Metastatic Urothelial Cancer · ACTIVE_NOT_RECRUITING · sponsor: Gilead Sciences · Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors

    ClinicalTrials.gov · NCT05101096 (opens the source filing in a new tab)

  11. Trial

    PHASE2 registered

    Oct 12, 2021

    Solid Tumor · ACTIVE_NOT_RECRUITING · sponsor: Gilead Sciences · Study of Sacituzumab Govitecan in Patients With Solid Tumor

    ClinicalTrials.gov · NCT05119907 (opens the source filing in a new tab)

  12. Trial

    PHASE1 registered

    Sep 15, 2021

    Solid Malignancies · TERMINATED · sponsor: Gilead Sciences · Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

    ClinicalTrials.gov · NCT05006794 (opens the source filing in a new tab)

  13. Trial

    PHASE1 registered

    Apr 6, 2021

    Advanced or Metastatic Solid Tumor, Liver Failure · RECRUITING · sponsor: Gilead Sciences · Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

    ClinicalTrials.gov · NCT04617522 (opens the source filing in a new tab)

  14. Trial

    PHASE2 registered

    Oct 23, 2020

    Metastatic Triple-negative Breast Cancer · ACTIVE_NOT_RECRUITING · sponsor: Gilead Sciences · Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

    ClinicalTrials.gov · NCT04454437 (opens the source filing in a new tab)

  15. Trial

    PHASE4 registered

    Aug 4, 2020

    Metastatic Solid Tumors · COMPLETED · sponsor: Gilead Sciences · Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy

    ClinicalTrials.gov · NCT04319198 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources